Global SERD (Selective Estrogen Receptor Degrader) Drugs Supply, Demand and Key Producers, 2023-2029

Page: 124

Published Date: 05 Feb 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global SERD (Selective Estrogen Receptor Degrader) Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global SERD (Selective Estrogen Receptor Degrader) Drugs demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for SERD (Selective Estrogen Receptor Degrader) Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of SERD (Selective Estrogen Receptor Degrader) Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global SERD (Selective Estrogen Receptor Degrader) Drugs total market, 2018-2029, (USD Million)
Global SERD (Selective Estrogen Receptor Degrader) Drugs total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: SERD (Selective Estrogen Receptor Degrader) Drugs total market, key domestic companies and share, (USD Million)
Global SERD (Selective Estrogen Receptor Degrader) Drugs revenue by player and market share 2018-2023, (USD Million)
Global SERD (Selective Estrogen Receptor Degrader) Drugs total market by Type, CAGR, 2018-2029, (USD Million)
Global SERD (Selective Estrogen Receptor Degrader) Drugs total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global SERD (Selective Estrogen Receptor Degrader) Drugs market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG and InventisBio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World SERD (Selective Estrogen Receptor Degrader) Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, Segmentation by Type
    RAD1901
    GDC-9545
    AZD9833
    SAR439859
    Faslodex
    Others

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, Segmentation by Application
    First-Line Treatment
    Second-Line Treatment

Companies Profiled:
    Amneal Pharmaceuticals Inc
    AstraZeneca, Plc.
    Dr. Reddy's Laboratories
    Eli Lilly and Company
    G1 Therapeutics, Inc.
    Glenmark Pharmaceuticals
    HBT Labs, Inc
    Hoffmann-La Roche AG
    InventisBio
    Novartis AG
    Radius Health
    Sanofi S.A.
    Teva Pharmaceutical Industries Ltd.
    Zenopharm LLC.
    Zentalis Pharmaceuticals

Key Questions Answered
1. How big is the global SERD (Selective Estrogen Receptor Degrader) Drugs market?
2. What is the demand of the global SERD (Selective Estrogen Receptor Degrader) Drugs market?
3. What is the year over year growth of the global SERD (Selective Estrogen Receptor Degrader) Drugs market?
4. What is the total value of the global SERD (Selective Estrogen Receptor Degrader) Drugs market?
5. Who are the major players in the global SERD (Selective Estrogen Receptor Degrader) Drugs market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
    1.2 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World SERD (Selective Estrogen Receptor Degrader) Drugs Total Market by Region (by Headquarter Location)
        1.3.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2018-2029)
        1.3.3 China SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2018-2029)
        1.3.4 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2018-2029)
        1.3.5 Japan SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2018-2029)
        1.3.6 South Korea SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2018-2029)
        1.3.7 ASEAN SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2018-2029)
        1.3.8 India SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 SERD (Selective Estrogen Receptor Degrader) Drugs Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)
    2.2 World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value by Region
        2.2.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value by Region (2018-2023)
        2.2.2 World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Forecast by Region (2024-2029)
    2.3 United States SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)
    2.4 China SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)
    2.5 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)
    2.6 Japan SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)
    2.7 South Korea SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)
    2.8 ASEAN SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)
    2.9 India SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029)

3 World SERD (Selective Estrogen Receptor Degrader) Drugs Companies Competitive Analysis
    3.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for SERD (Selective Estrogen Receptor Degrader) Drugs in 2022
        3.2.3 Global Concentration Ratios (CR8) for SERD (Selective Estrogen Receptor Degrader) Drugs in 2022
    3.3 SERD (Selective Estrogen Receptor Degrader) Drugs Company Evaluation Quadrant
    3.4 SERD (Selective Estrogen Receptor Degrader) Drugs Market: Overall Company Footprint Analysis
        3.4.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market: Region Footprint
        3.4.2 SERD (Selective Estrogen Receptor Degrader) Drugs Market: Company Product Type Footprint
        3.4.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Comparison
        4.2.1 United States VS China: SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies and Market Share, 2018-2023
        4.3.1 United States Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (2018-2023)
    4.4 China Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue and Market Share, 2018-2023
        4.4.1 China Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (2018-2023)
    4.5 Rest of World Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 RAD1901
        5.2.2 GDC-9545
        5.2.3 AZD9833
        5.2.4 SAR439859
        5.2.5 Faslodex
        5.2.6 Others
    5.3 Market Segment by Type
        5.3.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2018-2023)
        5.3.2 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2024-2029)
        5.3.3 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 First-Line Treatment
        6.2.2 Second-Line Treatment
    6.3 Market Segment by Application
        6.3.1 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2018-2023)
        6.3.2 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2024-2029)
        6.3.3 World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Amneal Pharmaceuticals Inc
        7.1.1 Amneal Pharmaceuticals Inc Details
        7.1.2 Amneal Pharmaceuticals Inc Major Business
        7.1.3 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.1.4 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Amneal Pharmaceuticals Inc Recent Developments/Updates
        7.1.6 Amneal Pharmaceuticals Inc Competitive Strengths & Weaknesses
    7.2 AstraZeneca, Plc.
        7.2.1 AstraZeneca, Plc. Details
        7.2.2 AstraZeneca, Plc. Major Business
        7.2.3 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.2.4 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 AstraZeneca, Plc. Recent Developments/Updates
        7.2.6 AstraZeneca, Plc. Competitive Strengths & Weaknesses
    7.3 Dr. Reddy's Laboratories
        7.3.1 Dr. Reddy's Laboratories Details
        7.3.2 Dr. Reddy's Laboratories Major Business
        7.3.3 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.3.4 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Dr. Reddy's Laboratories Recent Developments/Updates
        7.3.6 Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
    7.4 Eli Lilly and Company
        7.4.1 Eli Lilly and Company Details
        7.4.2 Eli Lilly and Company Major Business
        7.4.3 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.4.4 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Eli Lilly and Company Recent Developments/Updates
        7.4.6 Eli Lilly and Company Competitive Strengths & Weaknesses
    7.5 G1 Therapeutics, Inc.
        7.5.1 G1 Therapeutics, Inc. Details
        7.5.2 G1 Therapeutics, Inc. Major Business
        7.5.3 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.5.4 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 G1 Therapeutics, Inc. Recent Developments/Updates
        7.5.6 G1 Therapeutics, Inc. Competitive Strengths & Weaknesses
    7.6 Glenmark Pharmaceuticals
        7.6.1 Glenmark Pharmaceuticals Details
        7.6.2 Glenmark Pharmaceuticals Major Business
        7.6.3 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.6.4 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 Glenmark Pharmaceuticals Recent Developments/Updates
        7.6.6 Glenmark Pharmaceuticals Competitive Strengths & Weaknesses
    7.7 HBT Labs, Inc
        7.7.1 HBT Labs, Inc Details
        7.7.2 HBT Labs, Inc Major Business
        7.7.3 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.7.4 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 HBT Labs, Inc Recent Developments/Updates
        7.7.6 HBT Labs, Inc Competitive Strengths & Weaknesses
    7.8 Hoffmann-La Roche AG
        7.8.1 Hoffmann-La Roche AG Details
        7.8.2 Hoffmann-La Roche AG Major Business
        7.8.3 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.8.4 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Hoffmann-La Roche AG Recent Developments/Updates
        7.8.6 Hoffmann-La Roche AG Competitive Strengths & Weaknesses
    7.9 InventisBio
        7.9.1 InventisBio Details
        7.9.2 InventisBio Major Business
        7.9.3 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.9.4 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 InventisBio Recent Developments/Updates
        7.9.6 InventisBio Competitive Strengths & Weaknesses
    7.10 Novartis AG
        7.10.1 Novartis AG Details
        7.10.2 Novartis AG Major Business
        7.10.3 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.10.4 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Novartis AG Recent Developments/Updates
        7.10.6 Novartis AG Competitive Strengths & Weaknesses
    7.11 Radius Health
        7.11.1 Radius Health Details
        7.11.2 Radius Health Major Business
        7.11.3 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.11.4 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Radius Health Recent Developments/Updates
        7.11.6 Radius Health Competitive Strengths & Weaknesses
    7.12 Sanofi S.A.
        7.12.1 Sanofi S.A. Details
        7.12.2 Sanofi S.A. Major Business
        7.12.3 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.12.4 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.12.5 Sanofi S.A. Recent Developments/Updates
        7.12.6 Sanofi S.A. Competitive Strengths & Weaknesses
    7.13 Teva Pharmaceutical Industries Ltd.
        7.13.1 Teva Pharmaceutical Industries Ltd. Details
        7.13.2 Teva Pharmaceutical Industries Ltd. Major Business
        7.13.3 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.13.4 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
        7.13.6 Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
    7.14 Zenopharm LLC.
        7.14.1 Zenopharm LLC. Details
        7.14.2 Zenopharm LLC. Major Business
        7.14.3 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.14.4 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.14.5 Zenopharm LLC. Recent Developments/Updates
        7.14.6 Zenopharm LLC. Competitive Strengths & Weaknesses
    7.15 Zentalis Pharmaceuticals
        7.15.1 Zentalis Pharmaceuticals Details
        7.15.2 Zentalis Pharmaceuticals Major Business
        7.15.3 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
        7.15.4 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023)
        7.15.5 Zentalis Pharmaceuticals Recent Developments/Updates
        7.15.6 Zentalis Pharmaceuticals Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 SERD (Selective Estrogen Receptor Degrader) Drugs Industry Chain
    8.2 SERD (Selective Estrogen Receptor Degrader) Drugs Upstream Analysis
    8.3 SERD (Selective Estrogen Receptor Degrader) Drugs Midstream Analysis
    8.4 SERD (Selective Estrogen Receptor Degrader) Drugs Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key SERD (Selective Estrogen Receptor Degrader) Drugs Players in 2022
    Table 12. World SERD (Selective Estrogen Receptor Degrader) Drugs Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global SERD (Selective Estrogen Receptor Degrader) Drugs Company Evaluation Quadrant
    Table 14. Head Office of Key SERD (Selective Estrogen Receptor Degrader) Drugs Player
    Table 15. SERD (Selective Estrogen Receptor Degrader) Drugs Market: Company Product Type Footprint
    Table 16. SERD (Selective Estrogen Receptor Degrader) Drugs Market: Company Product Application Footprint
    Table 17. SERD (Selective Estrogen Receptor Degrader) Drugs Mergers & Acquisitions Activity
    Table 18. United States VS China SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Headquarters (States, Country)
    Table 21. United States Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share (2018-2023)
    Table 23. China Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Headquarters (Province, Country)
    Table 24. China Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share (2018-2023)
    Table 26. Rest of World Based SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share (2018-2023)
    Table 29. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2018-2023) & (USD Million)
    Table 31. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2024-2029) & (USD Million)
    Table 32. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2018-2023) & (USD Million)
    Table 34. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2024-2029) & (USD Million)
    Table 35. Amneal Pharmaceuticals Inc Basic Information, Area Served and Competitors
    Table 36. Amneal Pharmaceuticals Inc Major Business
    Table 37. Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 38. Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Amneal Pharmaceuticals Inc Recent Developments/Updates
    Table 40. Amneal Pharmaceuticals Inc Competitive Strengths & Weaknesses
    Table 41. AstraZeneca, Plc. Basic Information, Area Served and Competitors
    Table 42. AstraZeneca, Plc. Major Business
    Table 43. AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 44. AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. AstraZeneca, Plc. Recent Developments/Updates
    Table 46. AstraZeneca, Plc. Competitive Strengths & Weaknesses
    Table 47. Dr. Reddy's Laboratories Basic Information, Area Served and Competitors
    Table 48. Dr. Reddy's Laboratories Major Business
    Table 49. Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 50. Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Dr. Reddy's Laboratories Recent Developments/Updates
    Table 52. Dr. Reddy's Laboratories Competitive Strengths & Weaknesses
    Table 53. Eli Lilly and Company Basic Information, Area Served and Competitors
    Table 54. Eli Lilly and Company Major Business
    Table 55. Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 56. Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Eli Lilly and Company Recent Developments/Updates
    Table 58. Eli Lilly and Company Competitive Strengths & Weaknesses
    Table 59. G1 Therapeutics, Inc. Basic Information, Area Served and Competitors
    Table 60. G1 Therapeutics, Inc. Major Business
    Table 61. G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 62. G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. G1 Therapeutics, Inc. Recent Developments/Updates
    Table 64. G1 Therapeutics, Inc. Competitive Strengths & Weaknesses
    Table 65. Glenmark Pharmaceuticals Basic Information, Area Served and Competitors
    Table 66. Glenmark Pharmaceuticals Major Business
    Table 67. Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 68. Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. Glenmark Pharmaceuticals Recent Developments/Updates
    Table 70. Glenmark Pharmaceuticals Competitive Strengths & Weaknesses
    Table 71. HBT Labs, Inc Basic Information, Area Served and Competitors
    Table 72. HBT Labs, Inc Major Business
    Table 73. HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 74. HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. HBT Labs, Inc Recent Developments/Updates
    Table 76. HBT Labs, Inc Competitive Strengths & Weaknesses
    Table 77. Hoffmann-La Roche AG Basic Information, Area Served and Competitors
    Table 78. Hoffmann-La Roche AG Major Business
    Table 79. Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 80. Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Hoffmann-La Roche AG Recent Developments/Updates
    Table 82. Hoffmann-La Roche AG Competitive Strengths & Weaknesses
    Table 83. InventisBio Basic Information, Area Served and Competitors
    Table 84. InventisBio Major Business
    Table 85. InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 86. InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. InventisBio Recent Developments/Updates
    Table 88. InventisBio Competitive Strengths & Weaknesses
    Table 89. Novartis AG Basic Information, Area Served and Competitors
    Table 90. Novartis AG Major Business
    Table 91. Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 92. Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Novartis AG Recent Developments/Updates
    Table 94. Novartis AG Competitive Strengths & Weaknesses
    Table 95. Radius Health Basic Information, Area Served and Competitors
    Table 96. Radius Health Major Business
    Table 97. Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 98. Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 99. Radius Health Recent Developments/Updates
    Table 100. Radius Health Competitive Strengths & Weaknesses
    Table 101. Sanofi S.A. Basic Information, Area Served and Competitors
    Table 102. Sanofi S.A. Major Business
    Table 103. Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 104. Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 105. Sanofi S.A. Recent Developments/Updates
    Table 106. Sanofi S.A. Competitive Strengths & Weaknesses
    Table 107. Teva Pharmaceutical Industries Ltd. Basic Information, Area Served and Competitors
    Table 108. Teva Pharmaceutical Industries Ltd. Major Business
    Table 109. Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 110. Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 111. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
    Table 112. Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
    Table 113. Zenopharm LLC. Basic Information, Area Served and Competitors
    Table 114. Zenopharm LLC. Major Business
    Table 115. Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 116. Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 117. Zenopharm LLC. Recent Developments/Updates
    Table 118. Zentalis Pharmaceuticals Basic Information, Area Served and Competitors
    Table 119. Zentalis Pharmaceuticals Major Business
    Table 120. Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product and Services
    Table 121. Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 122. Global Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs Upstream (Raw Materials)
    Table 123. SERD (Selective Estrogen Receptor Degrader) Drugs Typical Customers
List of Figure
    Figure 1. SERD (Selective Estrogen Receptor Degrader) Drugs Picture
    Figure 2. World SERD (Selective Estrogen Receptor Degrader) Drugs Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World SERD (Selective Estrogen Receptor Degrader) Drugs Total Market Size (2018-2029) & (USD Million)
    Figure 4. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (2018-2029) & (USD Million)
    Figure 13. SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 16. World SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 18. China SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 23. India SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of SERD (Selective Estrogen Receptor Degrader) Drugs by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for SERD (Selective Estrogen Receptor Degrader) Drugs Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for SERD (Selective Estrogen Receptor Degrader) Drugs Markets in 2022
    Figure 27. United States VS China: SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: SERD (Selective Estrogen Receptor Degrader) Drugs Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type in 2022
    Figure 31. RAD1901
    Figure 32. GDC-9545
    Figure 33. AZD9833
    Figure 34. SAR439859
    Figure 35. Faslodex
    Figure 36. Others
    Figure 37. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type (2018-2029)
    Figure 38. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 39. World SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Application in 2022
    Figure 40. First-Line Treatment
    Figure 41. Second-Line Treatment
    Figure 42. SERD (Selective Estrogen Receptor Degrader) Drugs Industrial Chain
    Figure 43. Methodology
    Figure 44. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 04 Jan 2023

date Medical Care

According to our (Global Info Research) latest study, the global SERD (Selective Estrogen Receptor Degrader) Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global SERD (Selective Estrogen Receptor Degrader) Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 23 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global SERD (Selective Estrogen Receptor Degrader) Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

SERD (Selective Estrogen Receptor Degrader) Drugs

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>